Seller record · getzealthy.com

Zealthy

Recorded September 2026 · Standard v1.1

Fails 3 of 8 criteria. S3, pharmacy identification: Twelve pages were read, covering the questions, terms, telehealth consent, refunds, contact and privacy surfaces, and every reference to the filler reads partner pharmacy with no facility named. 2 more criteria also fail; see the table below.

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide beside brand GLP-1 prescriptions and several unrelated treatment lines. Its own pages name Zealthy, Inc. as the operator while the FDA letter addressed to this storefront names FitRX, LLC, and the two names are reconciled on no page read.

Operating entity Zealthy, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	getzealthy.com/weight-loss-faq
S2	Prescription gating	PASS	health.getzealthy.com/get-started
S3	Pharmacy identification	FAIL	getzealthy.com/terms-of-use
S4	Compounding disclosure	FAIL	getzealthy.com/weight-loss-faq
S5	Analytical documentation	FAIL	getzealthy.com/faqs
S6	Business address	PASS	getzealthy.com/privacy-policy
S7	Price disclosure	PASS	getzealthy.com/weight-loss-faq
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe weight-loss questions page states that providers are United States licensed, board certified physicians and nurse practitioners, and it names no individual prescriber.Source: getzealthy.com/weight-loss-faq.

S2PASSThe order path was walked and reached a health question about treatment goals, then an account screen, before any product page or payment field.Source: health.getzealthy.com/get-started.

S3FAILTwelve pages were read, covering the questions, terms, telehealth consent, refunds, contact and privacy surfaces, and every reference to the filler reads partner pharmacy with no facility named.Source: getzealthy.com/terms-of-use.

S4FAILThe word compounded appears throughout the weight-loss questions page, and no page read states that a compounded product lacks Food and Drug Administration approval.Source: getzealthy.com/weight-loss-faq.

S5FAILTwelve pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure.Source: getzealthy.com/faqs.

S6PASSThe privacy policy prints a street address with a floor at 30 Irving Place in New York, and the weight-loss page footer repeats it with a telephone number.Source: getzealthy.com/privacy-policy.

S7PASSThe weight-loss questions page prints a semaglutide bundle at 217 dollars for the first month and 297 dollars per month after, and a tirzepatide bundle at 349 dollars then 449 dollars.Source: getzealthy.com/weight-loss-faq.

S8PASSFDA warning letter 716501, September 2025, names FitRX, LLC doing business as Zealthy at the street address this site prints, and cites claims of the same active ingredient as an approved drug. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, brand GLP-1 prescriptions, birth control, hair loss and erectile dysfunction medications, mental health prescriptions.

Enforcement documents on file: 1 warning letter

FDA warning letter 716501, issued September 2025, to FitRX, LLC dba ZealthyClaims on getzealthy.com that compounded semaglutide is the same active ingredient as Wegovy and Ozempic are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.